Category Archives: Tropical Diseases

Medical practice changed for ever the moment AIDS arrived

Treatment Action Campaign activists in Cape Town South Africa, June 2012

 

The AIDS epidemic has changed practically every aspect of medical practice; from the way we view the disease, the accelerated global research to discover diagnostic tools, to unprecedented drug approval processes and speedy distribution and utilisation of new drugs. To date, manifestations of the AIDS virus are dealt with in practically all branches of medicine; unlike in the early years of the epidemic when cases were largely found in medical (internal medicine) wards, and even there they were isolated from the general patient population.

For example, the first AIDS cases admitted at the Kenyatta National Hospital were isolated in small dark cubicles in selected medical wards, often much against the wishes of the consultants in charge of the wards. No one physically touched the patients and medicines were placed on a stool and pushed inside the room by a nurse who stood clear of the door. Supposedly, the patient would reach the stool from his bed and collect not only the medicines, but also something to eat. When they died the corpse was placed in a black body-bag into which copious amounts of formalin would be poured. Relatives were not permitted to take the bodies for burial lest they spread the disease; the bodies had to be incinerated.

The AIDS virus has received the greatest attention of all time in medical history, more than any other pathogen; it has been as challenging to medical doctors, biomedical and social scientists, economists, theologians and philosophers alike, the pharmaceutical industry and drug regulatory authorities. Indeed, it is the combined effort of all these disparate groups and their quest to understand the disease that finally has shed some light at the end of the tunnel. As a result, today AIDS is not as perplexing as it once used to be. Within a span of under three decades HIV infection has changed from a death sentence to a chronic disease (at least where antiretroviral drugs-ARVs are readily available). This is unprecedented in medical history. For example, it took more than 400 years from the first recorded outbreak of syphilis in Europe (1494/1495) to identification of the causative organism, Treponema pallidum, in 1905 and discovery of the first effective treatment (Salvarsan) in 1910, before the wider availability of Penicillin in 1946. In contrast, the virus that is associated with AIDS was first identified by Montagnier et al. in France in 1983 and by Gallo et al. in the US in 1984, and within less than a decade, several drugs had already received FDA approval.

AIDS hit the world in 1981, first in California and New York in the United States. In 1982 the Centers for Disease Control (CDC) coined the term ‘acquired immunodeficiency syndrome’ (AIDS) and identified four “risk factors”: male homosexuality, intravenous drug use, Haitian origin, and hemophilia A. In 1983 a major outbreak of AIDS was reported among both men and women in central Africa, prompting the CDC to add female sexual partners of men with AIDS to its list of “risk groups”. Shortly afterwards, a history of blood transfusion and  female sex workers were added to the list, and before long the disease became a threat to all segments of society—though it still remains largely concentrated within the poorer and marginalised groups.

Kenyan Aids activists in Nairobi take their campaign in support of the Global Fund to the streets. Photograph: Sidi Sarrow

Amongst the significant impacts of AIDS on the practice of medicine, three can be pointed out, namely, increased precautionary actions by health care workers, safer blood supply (for blood transfusion), and disease activism. Specifically, the AIDS epidemic has impacted on medical practice in the following ways:

Safer infection prevention practices: Today health care workers have to treat all cases as being potentially infectious, and have to observe standard guidelines on infection prevention- to guard against cross-infection between cases, as well as protecting themselves from being infected by their patients. Hospital hygiene and safe injection practices, previously neglected in much of the developing world, have become topics of global concern. There are written instructions on how to handle blood and other bodily fluids, including the use of sterile gloves when handling blood and other body fluids, double gloving during surgery and wearing of visors to protect eyes from splashed blood. Health care workers are trained on safe handling of used needles and surgical blades (sharps), and there is a total ban on re use of syringes and needles. Hospitals would normally maintain registers of needle prick (stick) occurrences and administration of post-exposure ARV prophylaxis (PEP), etc. is administered to the staff involved.

In most countries today blood for transfusion is safer than previously. There has been more careful screening of blood for transfusion- to include besides HIV and syphilis- hepatitis B, A and C, malaria and other pathogens depending on the technological capability of the lab. This has been facilitated by creation of regionalised blood transfusion centres with capability for safe storage of larger volumes, and in contact with hospitals in the catchments areas.

The major challenge in countries like Kenya is ensuring sustained flow of resources to enable supply of the essential items needed for the above. Among the complaints raised by nurses and doctors in recent months are the lack of basic supplies such as protective gear- gloves, gowns and disinfectants. We must guard against slipping back to the days when gloves, syringes and needles were reused- as late as in the early 1990s! Fear of contracting HIV infection may influence choice of career. There have been anecdotal reports that today medicine is no longer the first choice for ‘A’ students in Kenya. A 1988 survey of house officers in the US, 25 percent of all respondents reported that they would not continue to care for AIDS patients if given a choice, while another study in 1991 reported that half of all primary care providers would not treat AIDS patients if they could avoid it[i]. A more recent study shows there is reluctance on the part of some nursing students in some regions of the world to provide care for people with HIV/AIDS, and recommends that educational programmes based on research evidence must play a leading role in developing strategies to help nursing students understand and overcome such attitudes[ii]. However, many would believe things have changed a lot for the better since then.

Disease activism:  In no other disease has there been as much advocacy as in the case of AIDS. For example, the response to the continuing presence of the so-called neglected tropical diseases (NTDs) stands in sharp contrast to the unparalleled achievement in addressing the HIV epidemic. Yet these diseases continue to cause massive but hidden and silent suffering, and frequently kill, largely because the people affected or at risk have little political voice. On the other hand, as mentioned above, the first cases of AIDS reported in the US involved highly educated men, many from the upper echelons of the American society. They soon realized their plight and, through a strong well organized lobby movement, fought hard for public attention and support of the search for ‘cure’. Within less than a decade their advocacy started bearing fruit. Patients also became more active participants in the research and drug development, sometimes not just being study subjects but actively helping in design of clinical trials.

Disease activism has played a major role in quickened drug approval processes, which was almost unheard of before AIDS patients spoke up, and is now becoming common among a whole range of other illnesses, including breast cancer. Although the strongest AIDS activism in Africa has largely been concentrated in South Africa, organised groups of PLWHA in other countries are increasingly becoming vocal in demanding increased access to ARVs as well as to TB and Malaria treatment. One area of success for global disease activism is increased availability of low priced generic drugs

Spill-over effects of research: Funding for AIDS research has surpassed expenditures for any other disease. According to UNAIDS in 2008, an estimated US$15.6 billion was spent on HIV and AIDS compared to US$300 million in 1996. However, a 2010 UNAIDS report warned that flattening of global funding for HIV research may limit ability of researchers to move promising approaches forward, especially in search for a vaccine.

The extensive research connected with AIDS has spilled over into a greater understanding of other chronic diseases especially cancer. Sexually transmitted diseases research, prevention and treatment is another area that has received renewed attention since AIDS, as sexual and reproductive health gained renewed prominence. The frequency with which Tuberculosis occurs in HIV-infected persons has led [1]to a resurgence of interest in the diagnosis and treatment of this ancient disease, while advances in the treatment of HIV-associated Opportunistic Infections have benefited other immune-suppressed persons.

Scientific advances have resulted in the development of lifesaving, albeit not curative, treatment for HIV. By the end of 2009, more than 5 million persons in low- and middle-income countries were accessing Antiretroviral Therapy (ART), unimaginable just a few years before and made possible through the use of generic drugs, price reductions for brand-name drugs, and efforts of international donors through initiatives such as the US PEPFAR and the Global Fund. The increasing availability of highly effective ARVs have transformed the way doctors look at HIV infection, and so too has terminal care changed. What had previously been an emphasis on simply maintaining life is increasingly shifting to give greater weight on quality of life, comfort and individual productivity.

Research on the prevention of mother-to-child transmission of HIV has led to interventions with the potential to virtually eliminate HIV disease in children (i.e. HIV-free generation). This should have a bearing on doctors’ attitudes towards childbearing for those infected with HIV, including investigating them for infertility. Research has identified viable options for HIV prevention in intravenous drug users, such as opioid substitution therapy and needle/syringe exchange.

Diminishing stigma: There was a time when doctors that treated AIDS cases were stigmatized and shun by other colleagues and patients. Even Hospital administrations quietly tried to discourage doctors from taking too many AIDS patients because it affected their facilities’ bottom lines. Today this is generally the least of their concerns. Even Insurance companies have opened up to people living with HIV albeit at much higher premium.

Typically, it has taken AIDS to bring the existence of marginalized groups such as sexual minorities to attention in low- and middle-income countries and to highlight their vulnerability and needs. They belong to what have been referred to as the ‘most at risk populations’ (MARPs), that include sex workers and their clients, men who have sex with men (MSM), and people who inject drugs (IDUs). It is recognised that failure to address these groups will compromise efforts towards reduction of new infections. As such it is unrealistic to operate as though they do not exist!

On the future: There is no better way of summarising the future of AIDS than to quote Dr Kevin M. De Cock, Director of the Center for Global Health at CDC in Atlanta: “Inevitably, the story of HIV/AIDS ‘could not be one of final victory. It could be only the record of what had to be done, and what assuredly would have to be done again in the never-ending fight against terror and its relentless onslaughts.’ An enduring frustration is that we will not know how the story of AIDS will finally end because the epidemic will outlast us. Yet the tide can be turned with principled pragmatism, adequate resources, trust in communities, and science as our guide”


[i] Infectious Disease News, June 2011, Infectious disease and the evolution of AIDS Thirty years since “patient zero,” how the world’s worst epidemic forever changed the specialty. http://www.healio.com/infectious-disease/hiv-aids/news/print/infectious-disease-news/%7BC1A89E60-E999-4FAB-A0FE-9DC54FD9AEED%7D/Infectious-disease-and-the-evolution-of-AIDS

[ii] Pickles D., King L. & Belani I. ( 2 0 0 9 ) Attitudes of nursing students towards caring for people with HIV/AIDS: thematic literature review. Journal of Advanced Nursing 65(11), 2262–2273. doi: 10.1111/j.1365-2648.2009.05128.x

 

Advertisements

What if the HIV epidemic first manifested in poor countries?

By Japheth Mati

The first WHO report on neglected tropical diseases[i] highlights the importance of a class of diseases which though medically diverse, are grouped together because all are strongly associated with poverty, all flourish in impoverished environments and all thrive best in tropical areas, where they tend to coexist. Most are ancient diseases that have plagued humanity for centuries. These diseases remain largely silent, as the people affected or at risk have little political voice. As a result, they have traditionally ranked low on national and international health agendas, allowing them to continue causing massive but hidden and silent suffering, and frequently kill, though not to the same extent as in the case of HIV and AIDS, tuberculosis or malaria.

The response to the continuing presence of the neglected tropical diseases (NTDs) in most countries in the Tropics stands in sharp contrast to the unparalleled achievement in addressing the HIV epidemic. The first case of AIDS was diagnosed in 1981. Two years later, in 1983 the HIV virus was identified, and in 1985 the FDA approved the first HIV antibody test, making it possible to diagnose the disease more precisely and to screen individuals (and blood) for the infection. In 1987 the FDA approved the first antiretroviral drug AZT (ziduvidine). Thus, despite remaining a serious global challenge, HIV had changed within a period of less than a decade from being essentially a fatal condition to become a chronic illness, thanks to the unprecedented global cooperation and commitment of massive resources for HIV research and development (R&D) activities.

Source:Working to overcome the global impact of neglected tropical diseases, First WHO report on neglected tropical diseases, 2010

Funding for Research & Development (R&D): HIV and AIDS versus NTDs

From the 1990s until 2009, funding for the HIV epidemic increased substantially[ii]. In 2008, an estimated $15.6 billion was spent on HIV and AIDS compared to $300 million in 1996. These funds mainly derived from donations from national governments, multilateral funding organisations, and private funding. In 2009 the United States of America was the largest donor in the world, accounting for more than half of disbursements to HIV R&D by governments. DFID is the world’s second biggest bilateral donor for HIV/AIDS.

On the other hand, R&D of drugs for NTDs has been very significantly under-funded. The first comprehensive survey of global spending on R&D for neglected diseases[iii], showed that in 2007, nearly 80% of the global investment into R&D of new medical products[iv] was consumed by three diseases- HIV/AIDS, TB, and malaria. Many NTDs, responsible for killing millions of people in developing countries, shared the remaining 20%; each received less than 5% of global funding. These diseases include Filariasis, Schistosomiasis, Onchocerciasis, Sleeping sickness, Leishmaniasis (kalar-azar), Chagas disease, Guinea-worm, Dengue, diarrhoeal illnesses, worm infestations, Pneumonia, Meningitis, Leprosy, Buruli ulcer, Trachoma, Rheumatic fever, Typhoid and Paratyphoid fever, and Rabies.

What is peculiar about the HIV epidemic?

AIDS as a disease entity was first reported in 1981 among homosexual men in the United States, and for some time the disease was considered peculiar to homosexuals, being variously labeled “the gay cancer”, “the gay plague” and “the gay-related immunodeficiency disease [GRID]”). These first cases involved highly educated men, many from the upper echelons of the American society. They soon realized their plight and, through a strong well organized lobby movement, fought hard for public attention and support of the search for ‘cure’. No wonder, within less than a decade, several drugs had already received FDA approval. Since then, HIV disease has engulfed the world, and the majority of the cases now live in developing countries. Nevertheless, it is possible that the conscience and momentum built up in those early years continue to play a significant role in sustaining international support for HIV activities.

What is peculiar about the neglected tropical diseases?

The nature of NTDs differs in several respects from HIV[v]. Generally, although these diseases affect the poor and marginalized populations living in rural and urban areas, they are almost exclusively limited to the tropics. These are people that cannot readily influence government decisions that affect their health, and often seem to have no constituency that speaks on their behalf. Also, unlike HIV, most NTDs generally do not spread widely, since their distribution is restricted by climate and its effect on the distribution of vectors and reservoir hosts; in most cases, there appears to be a low risk of transmission beyond the tropics. Consequently, not much is spoken about the impacts of the NTDs, nationally or internationally.

The neglected tropical diseases, also dubbed the ‘ancient companions of poverty’, have an enormous impact on individuals, families and communities in developing countries in terms of disease burden, quality of life, and loss of productivity aggravating poverty, as well as the high cost of long-term care. They constitute a serious obstacle to socioeconomic development and quality of life at all levels. WHO estimates that these diseases blight the lives of 1 billion people worldwide and threaten the health of millions more[vi]; they are a serious obstacle to the achievement of health-related Millennium Development Goals.

These diseases can, at relatively low cost, be controlled, prevented and possibly eliminated using effective and feasible solutions, such as the five strategic interventions recommended by WHO[vii].

What if the HIV epidemic first manifested in poor countries?

The answer to this philosophical question may never be known. However, going by the example of the dilatory international response to NTDs to date, it is worrying to imagine what the status of the HIV epidemic would be if it first manifested in poor countries.

[i] World Health Organization (2010) First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases WHO, Geneva 

[iv] Total investment was about $US 2.5 billion.

[v] World Health Organization (2010) First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases WHO, Geneva

[vi] World Health Organization (2010) First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases WHO, Geneva

[vii] These are: preventive chemotherapy; intensified case management; vector control; the provision of safe water, sanitation and hygiene; and veterinary public health.

%d bloggers like this: